IP Library Granted Patent US 8,709,404
Granted Patent B2
US 8,709,404 · App. 10/530,738 · Granted Apr 29, 2014

Immunotherapy in cancer treatment

Inventors: Ola Winqvist (Uppsala, SE); Magnus Thörn (Uppsala, SE)
Assignee: Sentoclone International AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,709,404
App. No.
10/530,738
Granted
Apr 29, 2014
Kind
B2
Abstract

The present invention relates to a novel method of cancer immuno-therapy and to a kit for use in this method. Specifically, the present invention relates to a novel method of collecting lymphocytes from sentinel lumph nodes and in vitro culture for the multiplication thereof lymphocytes.

Claims (17)

1. A method for treating cancer having a primary tumor in a human patient, comprising

(a) providing lymphocytes obtained from sentinel lymph nodes from the patient, wherein the sentinel lymph nodes are the first lymph nodes in the lymphatic system that receive lymphatic drainage from the primary tumor area;

(b) expanding the lymphocytes in vitro, wherein the lymphocytes are stimulated in vitro by addition of a stimulating agent selected from the group consisting of IL-2, IL-12, anti-CD3 antibody, and anti-CD28 antibody and are exposed to recombinant tumor antigen and/or autologous tumor extract, optionally presented with antigen presenting cells selected from B-cells, macrophages, monocytes, dendritic cells, or Langerhans cells; and

(c) transferring the expanded lymphocytes into the patient.

2. The method of claim 1 , wherein the lymphocytes are stimulated with IL-2.

3. The method of claim 1 , wherein the lymphocytes are stimulated with anti-CD3 antibody.

4. The method of claim 1 , wherein the lymphocytes are stimulated with anti-CD28 antibody.

5. The method of claim 1 , wherein the lymphocytes are first exposed to autologous tumor extract and then are stimulated with IL-2.

6. The method of claim 1 , wherein the lymphocytes are exposed to recombinant tumor antigen.

7. The method of claim 1 , wherein the lymphocytes are exposed to autologous tumor extract.

8. The method of claim 1 , wherein the sentinel lymph nodes are free of tumor cells.

9. The method of claim 1 , wherein the lymphocytes are separated from the stimulating agent after stimulation.

10. The method of claim 9 , wherein the lymphocytes are separated from recombinant tumor antigen and/or autologous tumor extract after exposure.

11. The method of claim 9 , wherein after separation, the lymphocytes are restimulated by a further addition of the stimulating agent.

12. The method of claim 11 , wherein the further addition of the stimulating agent is made with addition of medium to a culture of the lymphocytes.

13. The method of claim 12 , wherein the lymphocytes are restimulated with IL-2.

14. The method of claim 9 , wherein after separation, the lymphocytes are restimulated by a further addition of IL-2.

Assignments (6)
CHANGE OF NAME Recorded Jun 28, 2011
From: DEIFIERA FALUN AB
To: SENTOCLONE INTERNATIONAL AB
Reel/Frame 026511/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2011
From: SENTOCLONE AB
To: DEIFIERA FALUN AB
Reel/Frame 025752/0140 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 023239 FRAME 0847. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME DOCUMENT WAS RECORDED ON 9/16/2009 WITH THE INCORRECT ADDRESS. Recorded Sep 22, 2009
From: SENTOCLONE THERAPEUTICS AB
To: SENTOCLONE AB
Reel/Frame 023268/0029 →
CHANGE OF NAME Recorded Sep 16, 2009
From: SENTOCLONE THERAPEUTICS AB
To: SENTOCLONE AB
Reel/Frame 023239/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2007
From: SAHLTECH I GOTEBORG AB
To: SENTOCLONE THERAPEUTICS AB
Reel/Frame 019209/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2007
From: WINQVIST, OLA; THORN, MAGNUS
To: SAHLTECH I GOTEBORG AB
Reel/Frame 019173/0985 →
Priority Claims (1)
EP 02022787 · Oct 11, 2002 · regional
Continuity (1)
Related Publication 20070141026A1 · Jun 21, 2007